COMPASS Pathways

Compass Pathways Plc functions as an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

COMPASS Pathways reports Q4 earnings, faces challenges, explores opportunities

COMPASS Pathways showcased progress in its clinical programs, financial performance, and strategic initiatives. Despite challenges in trial protocols and financial losses, the company remains focused on advancing its treatment options and exploring growth opportunities.

COMPASS Pathways advances Phase 3 TRD program amidst financial challenges

COMPASS Pathways is making progress in their Phase 3 TRD program and maintaining a strong financial position for future developments.
Acceptance of new CPT codes and engagement with health systems present growth opportunities for the company.
However, challenges like financial losses, mixed views on commercialization, and operational differences exist.
Overall, COMPASS Pathways is strategically positioned to capitalize on the evolving landscape of psychedelic therapies.

COMPASS Pathways progresses in trials amidst market challenges and opportunities

COMPASS Pathways is advancing well in trials for treatment-resistant depression and strengthening its market position through IP protection and regulatory milestones.
Challenges lie in differentiation from competitors and establishing unique value propositions, but opportunities exist in FDA support, market growth, and funding flexibility.
Overall, the company's performance, financial stability, and strategic moves position it favorably in the evolving landscape of psychedelic therapies.

COMPASS Pathways reports strong Q3 earnings, eyes transformative 2024

COMPASS Pathways demonstrated robust financial performance in Q3 2023, with strong cash reserves and a strategic private placement financing, positioning the company well for upcoming milestones.
While facing challenges in patient recruitment and trial complexities, COMPASS is leveraging AI models and expanding clinical sites to optimize operations and drive therapeutic innovation.
With Phase III data on the horizon and ongoing advancements in research and development, COMPASS Pathways is poised for a transformative year in 2024, capitalizing on growth opportunities and research insights.

COMPASS Pathways advances COMP360 trials amid financial challenges

COMPASS Pathways' financials show investment in research and development despite net losses, with a strong cash position.
Progress in key trials for COMP360 in TRD and positive safety data indicate promising developments in mental health treatment.
Challenges in enrollment, delays in data, and regulatory monitoring require strategic navigation for future success.
Opportunities lie in collaborations, potential indications, and a focused approach to TRD treatment with COMP360.

COMPASS Pathways advances in clinical trials and strategic partnerships

COMPASS Pathways showcased strong clinical and financial performance in Q1 2024 earnings call, emphasizing progress in Phase III trials and positive PTSD study results
While facing challenges in risk mitigation and therapy comparisons, the company's strategic collaborations and upcoming data releases offer promising opportunities for growth

Compass Pathways faces trial delays, strengthens leadership for commercial success

Compass Pathways navigates delays in pivotal trials while focusing on data disclosure and commercial readiness. New leadership strengthens strategic direction and commercial landscape. Challenges include trial complexities and managing attrition rates, with opportunities in leveraging Phase III data and commercial collaborations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

London, UK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in two investor conferences during the week of 11 January 2021.

COMPASS Pathways plc to participate in HC Wainwright and ICR investor conferences

Psilocybin Will Change Mental Health, Compass Pathways Could Be At The Forefront

These psychedelic stocks are worth accumulating on corrections. The companies are holding clinical trials for mental health drugs.

3 Psychedelic Stocks Taking Mental Health Seriously

This small-cap biotech may very well revolutionize how we treat depression.

Is Compass Pathways Stock a Buy?

COMPASS Pathways is a biotech psychedelic medicine development and therapy company that has developed a synthetic formulation of psilocybin, COMP360, for combatting treatment-resistant depression. Received the highly-valuable FDA Breakthrough Therapy Designation for COMP360 trials and is currently in Phase 2a trials.

COMPASS Pathways: Risky But Can Pay Back Generously

Psychedelic stocks are going to surge as the once "hardcore" group of pschedelic drugs gains widespread mainstream medicinal acceptance. The post Find Your Next 10X Winner in the Burgeoning Shroom Boom appeared first on InvestorPlace.

Find Your Next 10X Winner in the Burgeoning Shroom Boom

The company's fresh look at psychedelic drugs is attracting lots of attention.

Is Compass Pathways a Good Stock to Buy Now?

The market is in its early stage, and the players in the space could have a lot of room to run.

Missed Out on Marijuana Stocks? Psychedelic Stocks Could Be the Next Big Thing

Could psilocybin therapy become a hyper-growth market in mental health medicine? It could happen, so consider a position in CMPS stock.

Trade the Burgeoning ‘Shroom Boom' with COMPASS Pathways Stock

Highlights include $146.6 million IPO, continued progress with phase IIb psilocybin therapy clinical trial, strengthened board and leadership team, and launch of Drug Discovery Center Highlights include $146.6 million IPO, continued progress with phase IIb psilocybin therapy clinical trial, strengthened board and leadership team, and launch of Drug Discovery Center

COMPASS Pathways plc announces financial results for third quarter 2020

COMPASS Pathways joins the Psychiatry Consortium in a collaboration to accelerate drug discovery in mental health care

London, UK, Nov. 05, 2020 (GLOBE NEWSWIRE) --   COMPASS Pathways plc to announce third quarter 2020 financial results on 12 November 2020

COMPASS Pathways plc to announce third quarter 2020 financial results on 12 November 2020

Voters in Oregon approved a ballot measure that legalizes a treatment this newly public company has in clinical trials.

This Biotech Stock Was a Winner Last Night

London, UK, Nov. 04, 2020 (GLOBE NEWSWIRE) --   COMPASS Pathways plc to participate in Berenberg and Evercore investor conferences

COMPASS Pathways plc to participate in Berenberg and Evercore investor conferences

NEW YORK, Nov. 2, 2020 /PRNewswire/ -- For decades, psychedelic therapy was only an experimental idea under research by organizations at academic institutions including Johns Hopkins. This changed in 2018 after life sciences company COMPASS Pathways plc (NASDAQ:CMPS) received Breakthrough...

Psychedelic Therapies Become New Biotech Hotspot Amid New Legitimacy

COMPASS Pathways plc to ring Nasdaq Stock Exchange opening bell in celebration of its successful $146.6 million IPO

The trailblazing company studying the use of the psychedelic drug found in magic mushrooms to treat mental health is starting to make waves.

Why COMPASS Pathways Mushroomed Almost 20% Today

Neuronetics Inc

The following originally appeared on CapitalWatch An increasing number of Americans becoming increasingly anxious or depressed or worse. To wit, there were more than 72,000 fatal overdoses in 2019 and more than 48,000 suicides in 2018.

These Small Caps Are Betting Big On America Losing Its Mind

In mid-September, the true leader of the Shroom Boom -- COMPASS Pathways (NASDAQ:CMPS) -- finally came public via an IPO that was a huge success. The post Thanks to the Shroom Boom, This Small Stock Could Soar appeared first on InvestorPlace.

Thanks to the Shroom Boom, This Small Stock Could Soar

NEW YORK, Oct. 7, 2020 /PRNewswire/ -- Depression, anxiety, post-traumatic stress disorder (PTSD), and other mental illnesses have been prevalent in the US for quite some time, but the coronavirus pandemic has triggered a full-blown mental health crisis. Prior to the viral outbreak, the...

Compass Pathways' Historic IPO Shines Spotlight on Alternative Mental Health Treatments

A short-seller likes the recent IPO stock.

Why Compass Pathways Stock Is Soaring Today

 COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares

CMPS stock shot up more than 70% during its first trading. Here is what else investors need to know about the recent Compass Pathways IPO.

Compass Pathways IPO: 5 Things for Potential CMPS Investors to Know

Investors are piling into this newly public psychedelic medicine stock.

Why Compass Pathways Is Soaring Today

Shares of Compass Pathways PLC CMPS, +42.91% pointed north out of the gate, as the first trade was 37.6% above the initial public offering price.

News for COMPASS Pathways Stock (CMPS)